Lower-dose chemotherapy before CAR T-cell therapy in people with kidney problems
Tests adjusted chemotherapy before CAR T-cell therapy in adults with B-cell cancers.
Key facts
- Who runs it
- Northside Hospital, Inc.
- Where
- Atlanta, United StatesSee the site
- Trial code
- Registry title
- CAR T-cell Therapy in Patients With Renal Dysfunction
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 18 Nov 2024
- Expected to end
- 31 Aug 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- Fludarabine
- Cyclophosphamide
- Record updated
- 14 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma, leukemia or lymphoma who will get CAR-T therapy and have reduced kidney function.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma, leukemia or lymphoma, with kidney function of 60 mL/min/1.73m2 or lower.
- Earlier treatment
- People must be getting lymphodepleting chemotherapy before commercial CAR-T treatment. Those on therapeutic-dose steroids (more than 20mg/day prednisone or equivalent) within 72 hours of CAR-T cannot join.
Main reasons for not taking part
- Relative CNS disorders
- Active uncontrolled infection or another illness that could interfere with the study
- Therapeutic-dose systemic steroids (more than 20mg/day prednisone or equivalent) within 72 hours of CAR-T
- Bone marrow function not adequate for lymphodepleting chemotherapy
- ECOG score above 2
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma
- Adequate bone marrow function to receive lymphodepleting chemotherapy
- Renal function </= 60mL/min/1.73m2
- ECOG 0-2
Who cannot take part
- Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator
- Use of therapeutic dose systemic corticosteroids (defined as >20mg/day prednisone or equivalent) within 72 hours of CAR-T administration
- Relative CNS disorders
Where in United States
- Caitlin GuzowskiAtlanta, United StatesContact: Caitlin Guzowski, MBA, MHATaking people
About the trial
What the trial wants to find out
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
The 3 groups in the trial
- Moderate Renal DysfunctionTreatment being tested
Moderate renal dysfunction will receive a 20% dose reduction of fludarabine and no dose reduction for cyclophosphamide.
Treatment: Fludarabine and Cyclophosphamide
- Severe Renal DysfunctionTreatment being tested
Several renal dysfunction will receive a 40% dose reduction of fludarabine and no dose reduction for cyclophosphamide.
Treatment: Fludarabine and Cyclophosphamide
- Dialysis ParticipantsTreatment being tested
Participants on dialysis will receive a 50% dose reduction of fludarabine and a 25% dose reduction of cyclophosphamide.
Treatment: Fludarabine and Cyclophosphamide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction
- Plain-language title
- Lower-dose chemotherapy before CAR T-cell therapy in people with kidney problemsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 October 2026